<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5BNLMID%5D&amp;utm_source = Chrome＆utm_camp aign =日记＆utm_medium = rss＆ff = 20250415082127＆utm_content = 101560960＆v = 2.18.0.post9+e462414＆fc = none<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_source=Chrome&amp;utm_campaign=journals&amp;utm_medium=rss&amp;ff=20250415082127&amp;utm_content=101560960&amp;v=2.18.0.post9+e462414&amp;fc=None" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期二，2025年4月15日12:21:28 +0000</lastbuilddate><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>小细胞外囊泡miRNA作为生物标志物，用于预测用化学疗法治疗的肺腺癌和检查点阻滞的抗肿瘤功效</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230863/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>与化学疗法结合的检查点阻滞已成为临床环境中肺癌患者的重要治疗选择。但是，有效地识别真正响应者的生物标志物仍然缺乏。我们评估了血浆小细胞外囊泡（SEV）衍生的microRNA（miRNA）的潜力，作为预测和鉴定对免疫化学疗法组合的反应者的生物标志物。共有29例肺腺癌患者接受了pembrolizumab，并结合了Pemetrexed ... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1573043。 doi：10.3389/fimmu.2025.1573043。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">与化学疗法结合的检查点阻滞已成为临床环境中肺癌患者的重要治疗选择。但是，有效地识别真正响应者的生物标志物仍然缺乏。我们评估了血浆小细胞外囊泡（SEV）衍生的microRNA（miRNA）的潜力，作为预测和鉴定对免疫化学疗法组合的反应者的生物标志物。总共29例接受pembrolizumab的肺腺癌患者，并结合了Pemetrexed和Carboplatin。功效评估表明，24名患者从合并的免疫化学疗法中获得了持久的临床益处，其余患者经历了疾病的进展。使用无监督的分层聚类，在响应者和非反应者之间鉴定了56个差异表达的miRNA（DEM）。建立了结合SEV miRNA组合的功效预测模型，并表现出良好的性能（曲线下的面积（AUC）>; 0.9）。此外，我们发现miR-96-5p和miR-6815-5p在非反应组中显着下调，而miR-99b-3p，miR-100-5p，miR-100-5p，miR-193a-5p和miR-320d被上调。通过临床成像进一步证实了这些发现。源自肺癌患者的SEV miRNA表现出有望鉴定真正反应者对免疫化学疗法组合的反应者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230863/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230863</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994727/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994727</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1573043>10.3389/fimmu.2025.1573043</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230863</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Si Sun</dc:creator><dc:creator> Fuchuang Zhang</dc:creator><dc:creator>张张</dc:creator><dc:creator>hui yu</dc:creator><dc:creator> Zhihuang Hu</dc:creator><dc:creator> xiaoya xu</dc:creator><dc:creator> Xinmin Zhao</dc:creator><dc:creator>陈陈</dc:creator><dc:creator>张张</dc:creator><dc:creator>隆恩·尼恩（Nian）</dc:creator><dc:creator> ying lin</dc:creator><dc:creator> Zhikuan li</dc:creator><dc:creator> Zhenhua Wu</dc:creator><dc:creator> Bo Yu</dc:creator><dc:creator>武瓦</dc:creator><dc:creator>Huijie Wang</dc:creator><dc:creator> xiaohua hui</dc:creator><dc:creator> Dadong Zhang</dc:creator><dc:creator> Jialei Wang</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>小细胞外囊泡miRNA作为生物标志物，用于预测用化学疗法治疗的肺腺癌和检查点阻滞的抗肿瘤功效</dc:title><dc:identifier>PMID：40230863</dc:identifier><dc:identifier> PMC：PMC11994727</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1573043</dc:identifier></item><item><title>表型异质性和肿瘤免疫微环境指示胰腺导管腺癌的治疗策略</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230862/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>胰腺癌是一种侵袭性肿瘤，具有较高的转移性潜力，可降低存活率和对化学疗法和免疫疗法的抵抗力。近90％的胰腺癌包括胰腺导管腺癌（PDAC）。大约80％的诊断是在无法切除的晚期转移阶段进行的，这使化学疗法方案无效。还缺乏针对早期检测的特定生物标志物。下一代测序的进步... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1573522。 doi：10.3389/fimmu.2025.1573522。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">胰腺癌是一种侵袭性肿瘤，具有较高的转移性潜力，可降低存活率和对化学疗法和免疫疗法的抵抗力。近90％的胰腺癌包括胰腺导管腺癌（PDAC）。大约80％的诊断是在无法切除的晚期转移阶段进行的，这使化学疗法方案无效。还缺乏针对早期检测的特定生物标志物。下一代测序和单细胞分析的进步已经确定了在PDAC进展和亚型可塑性中起作用的分子改变和特征。大多数化学疗法方案仅显示出适度的生存益处，因此，迫切需要采用免疫疗法和联合疗法的翻译方法。在这篇综述中，我们研究了具有各种代谢和转录变化的肿瘤免疫微环境的免疫抑制和致密的基质网络，这些变化构成了PDAC中PRORORIGINIC特性的基础，该特性就表型异质性，可变性和亚型共存在而言。此外，讨论了影响PDAC发育的基质异质性以及遗传和表观遗传变化。我们还回顾了与肿瘤免疫微环境中存在的隔离细胞和体液成分的PDAC相互作用，从而改变了化学疗法和放射疗法的结果。最后，我们讨论针对旨在更好预后和改善PDAC生存率的肿瘤免疫微环境的不同治疗干预措施。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230862/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230862</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994623/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994623</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1573522>10.3389/fimmu.2025.1573522</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230862</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> REMYA PG RAMESH</dc:creator><dc:creator> hadida yasmin</dc:creator><dc:creator>漂亮的潘纳汉</dc:creator><dc:creator>巴塞尔al-Ramadi</dc:creator><dc:creator> Uday Kishore</dc:creator><dc:creator>安玛丽·约瑟夫</dc:creator><dc:date>2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>表型异质性和肿瘤免疫微环境指示胰腺导管腺癌的治疗策略</dc:title><dc:identifier>PMID：40230862</dc:identifier><dc:identifier> PMC：PMC11994623</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1573522</dc:identifier></item><item><title>免疫调节因素单核苷酸多态性对急性髓样白血病的治疗反应和预后的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230861/?utm_source = chrome&amp;utm_medium = rsss&amp;utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>结论：我们关于HMOX1，TXNIP，TNSF10/TRAIL和TNFAIP2基因中AML与SNP之间关联的结果为预测AML患者的治疗反应和预后提供了重要参考。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1571332。 doi：10.3389/fimmu.2025.1571332。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：急性髓样白血病（AML）是一种血液学恶性肿瘤，其特征是总生存期（OS）。 T细胞的功能受损，表型改变和异常分布在AML中产生了免疫抑制的微环境，影响了化学疗法的功效。研究表明，分化的单核细胞样AML细胞可以表达各种免疫调节因子，从而导致T细胞表型变化和免疫抑制AML微环境的发展。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在255名非M3 AML患者和316位健康对照组中选择并分析了四个免疫调节因子HMOX1，TXNIP，TNSF10/TRAIL和TNFAIP2的七个单核苷酸多态性（SNP）。使用MassArray平台进行了SNP基因分型。此外，我们分析了AML敏感性，骨髓（BM）爆炸百分比，临床特征，治疗反应以及所选SNP的预后之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：研究表明，HMOX1 RS2071746和TNFAIP2 RS1132339与AML患者诊断时与BM爆炸有关。 TXNIP RS7211与对AML中细胞押滨和蒽环类化疗的敏感性有关，而TXNIP rs9245与AML复发有关。此外，TRAIL/TNFSF10 RS12488654与AML患者的整体存活有关，而TRAIL/TNFSF10 RS12488654的AA基因型可能是AML预测的独立因素。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们关于HMOX1，TXNIP，TNSF10/TRAIL和TNFAIP2基因中AML与SNP之间关联的结果为预测AML患者的治疗反应和预后提供了重要参考。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230861/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230861</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994645/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994645</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1571332>10.3389/fimmu.2025.1571332</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230861</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> li</dc:creator><dc:creator>陶太阳</dc:creator><dc:creator>Mengyuan Chang</dc:creator><dc:creator> liu</dc:creator><dc:creator> Lei Feng</dc:creator><dc:creator>迪张</dc:creator><dc:creator>Yuyan Wu</dc:creator><dc:creator> Yuechan MA</dc:creator><dc:creator> Huixian MA</dc:creator><dc:creator>广q门</dc:creator><dc:creator>Chunyan JI</dc:creator><dc:creator> jingjing ye</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>免疫调节因素单核苷酸多态性对急性髓样白血病的治疗反应和预后的影响</dc:title><dc:identifier>PMID：40230861</dc:identifier><dc:identifier> PMC：PMC11994645</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1571332</dc:identifier></item><item><title> GLP-1和胰高血糖素受体双重激动剂通过改善脂质代谢来改善肾脏同种异体移植纤维化</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230860/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>结论：使用GLP-1R/GCGR双重激动剂TB001靶向代谢途径显示出管理肾脏同种异体纤维化的潜力。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1551136。 doi：10.3389/fimmu.2025.1551136。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：肾脏同种异体移植纤维化加速了慢性肾脏疾病（CKD）的进展，导致同种异体移植衰竭，并增加了患者死亡率。新兴的证据表明，移植受者中的代谢综合征与纤维化发育有关。但是，尚不清楚靶向代谢途径是否可以减轻同种异体移植纤维化。这项研究旨在探索使用GLP-1R/GCGR双激动剂TB001靶向代谢途径的潜力，以治疗肾脏同种异体移植纤维化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在大鼠肾移植模型中诱导肾脏同种异体纤维化。进行了组织学分析，转录组测序和<i>体外</i>实验，以研究TB001及其潜在机制的功效。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与对照组相比，TB001处理的受体具有显着改善的肾脏同种异体移植功能，这证明了肌酐较低和24小时的尿液蛋白水平。此外，TB001治疗减少了移植受者的体重和血清总胆固醇，LDL-胆固醇和TNF-α水平，表明代谢改善。病理分析表明，TB001治疗降低了炎症细胞的浸润，并下调了纤维化标记物的表达，包括TGF-β1，α-SMA，Col1a1和Vimentin。肾脏移植物的进一步转录组测序表明，经TB001处理的组具有类似于Syngeneic对照组的基因表达模式，并且显示出与脂质代谢相关的途径的显着增强，尤其是PPAR途径。<i>体内</i>和<i>体外</i>实验进一步表明，TB001上调了CPT1A的表达，CPT1a是脂质代谢涉及的关键分子，并抑制了TGF-β1/SMAD2/SMAD2/3/Twist和PKC-α/PKC-β途径。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：使用GLP-1R/GCGR双重激动剂TB001靶向代谢途径显示出管理肾脏同种异体纤维化的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230860/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230860</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994718/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994718</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1551136>10.3389/fimmu.2025.1551136</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230860</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Linjie Peng</dc:creator><dc:creator> Weijie Lai</dc:creator><dc:creator> shuangjin yu</dc:creator><dc:creator> Qihao li</dc:creator><dc:creator>徐敏江</dc:creator><dc:creator>古迪恩·陈</dc:creator><dc:date>2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>GLP-1和胰高血糖素受体双重激动剂通过改善脂质代谢来改善肾脏同种异体移植纤维化</dc:title><dc:identifier>PMID：40230860</dc:identifier><dc:identifier> PMC：PMC11994718</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1551136</dc:identifier></item><item><title>使用抗乙酰胆碱受体抗体开发了重症肌无力的肌无力的实验小鼠模型</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230859/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>肌无力重症（MG）是一种自身免疫性疾病，主要由靶向乙酰胆碱受体（ACHR）的自身抗体引起的神经肌肉连接（NMJ）。经典的实验性自身免疫性肌无力肌无力重症（C-EAMG）小鼠模型长期以来，已从鱼雷鱼（T-ACHR）与完全弗雷德的佐剂（CFA）相结合的乙酰胆碱受体免疫小鼠。该混合物是通过皮下注射到后脚垫和背部的，但是CFA通常会导致... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1521382。 doi：10.3389/fimmu.2025.1521382。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">肌无力重症（MG）是一种自身免疫性疾病，主要由靶向乙酰胆碱受体（ACHR）的自身抗体引起的神经肌肉连接（NMJ）。经典的实验性自身免疫性肌无力肌无力重症（C-EAMG）小鼠模型长期以来，已从鱼雷鱼（T-ACHR）与完全弗雷德的佐剂（CFA）相结合的乙酰胆碱受体免疫小鼠。该混合物是通过皮下注射到后脚垫和背部的，但是CFA通常会引起强烈的炎症反应，包括注射部位的病变。我们的目标是开发一种新的EAMG模型（N-EAMG），该模型更符合动物福利。 C57BL/6小鼠每周两次通过腹膜内（IP）注射poly（i：c）和脂多糖（LPS）辅助混合物T-ACHR。对照小鼠仅注射生理盐水或辅助混合物。测试了各种剂量和注射时间表，并将新模型与C-EAMG进行了比较。对临床症状进行评分，测量针对T-ACHR和小鼠ACHR的抗体亚型，并评估NMJ的形态和功能。我们证明了N-EAMG模型至少与C-EAMG模型一样有效。此外，类似于C-EAMG模型，N-EAMG模型的特征是T-ACHR和M-ACHR抗体的产生。由于抗体攻击，该模型还显示出NMJ的传播变化，从而导致ACHR表面积减少并增加ACHR碎片。在这两个模型中的症状都相似，但在N-EAMG模型中的出现更快。此外，研究了敏化机制，我们表明对T-ACHR注射poly（i：c）/LPS辅助混合物，导致单核细胞的募集以及两个能够吞噬T-ACHR的腹膜巨噬细胞亚群的变化。这些观察结果表明，巨噬细胞亚型尽管效率有所不同，但仍将T-ACHR呈现给免疫细胞，从而导致特定的免疫反应和抗ACHR抗体的发展。总之，我们的结果表明，这种新颖的EAMG模型与C-EAMG模型一样有效，并提供了几个优势。特别是，该模型更适合动物福利，可以替代临床前和基本研究中的经典模型。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230859/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230859</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994731/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994731</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1521382>10.3389/fimmu.2025.1521382</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230859</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator>阿克尔你</dc:creator><dc:creator>LéaSlippens</dc:creator><dc:creator>敖德萨 - 穆德·法耶特（Odessa-Maud Fayet）</dc:creator><dc:creator> SolèneMaillard</dc:creator><dc:creator>劳琳·贝特姆斯（Laureline Betemps）</dc:creator><dc:creator>安东尼格朗丁</dc:creator><dc:creator>让·托马斯·维尔奎因</dc:creator><dc:creator>纳丁·德拉宾（Nadine Dragin）</dc:creator><dc:creator> Rozen Le Panse</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>使用抗乙酰胆碱受体抗体开发了重症肌无力的肌无力的实验小鼠模型</dc:title><dc:identifier>PMID：40230859</dc:identifier><dc:identifier> PMC：PMC11994731</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1521382</dc:identifier></item><item><title>外周B淋巴细胞和B淋巴细胞子集的畸变帕金森氏病：系统评价</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230858/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>结论：审查的研究表明，PD与外周血中B淋巴细胞和/或B淋巴细胞亚群的异常有关。这项研究提供了对PD发病机理的新观点，并且对PD的生物标志物和治疗靶标进行了对B淋巴细胞和/或B淋巴细胞亚群的未来研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1526095。 doi：10.3389/fimmu.2025.1526095。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：B淋巴细胞与B淋巴细胞亚群和帕金森氏病（PD）的关联越来越多地得到认可。但是，PD患者的外周血中B淋巴细胞或B淋巴细胞亚群的改变存在不一致。为了全面了解其在PD患者中的变化，有必要对该主题进行系统的审查。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：搜索PubMed，Cochrane库和MEDLINE数据库，直到2024年2月3<sup>日</sup>。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们包括20项研究（n = 2658）来进行此系统综述。我们进行了定性分析，以评估PD个体的外周血中B淋巴细胞和B淋巴细胞亚群的改变。综述的研究表明，这些患者外周血的B淋巴细胞亚群中B细胞的数量显着减少，并且免疫失调。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：审查的研究表明，PD与外周血中B淋巴细胞和/或B淋巴细胞亚群的异常有关。这项研究提供了对PD发病机理的新观点，并且对PD的生物标志物和治疗靶标进行了对B淋巴细胞和/或B淋巴细胞亚群的未来研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230858/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230858</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994702/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994702</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1526095>10.3389/fimmu.2025.1526095</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230858</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Hongxia MA</dc:creator><dc:creator> Ziyuan Wang</dc:creator><dc:creator> Miao Yu</dc:creator><dc:creator> Yibo Zhai</dc:creator><dc:creator> Junqiang Yan</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>外周B淋巴细胞和B淋巴细胞子集的畸变帕金森氏病：系统评价</dc:title><dc:identifier>PMID：40230858</dc:identifier><dc:identifier> PMC：PMC11994702</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1526095</dc:identifier></item><item><title>免疫检查点抑制剂在晚期胆道癌中的功效和安全性：一项现实研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230857/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>结论：ICIS在现实世界中表现出强大的功效和可管理的毒性，支持它们在先进BTC的第一和后期治疗中的使用。但是，国内ICI替代方案是否仍然可行，需要进一步验证。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1493234。 doi：10.3389/fimmu.2025.1493234。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：与吉西他滨和顺铂化疗相结合的免疫检查点抑制剂（ICI）已成为晚期胆道癌（BTC）的标准一线治疗方法。但是，关于中国广泛使用的国内ICI的现实证据，跨治疗线的治疗结果仍然有限。这项研究旨在评估ICI在晚期BTC患者中的现实有效性和安全性，同时阐明不同ICI亚型之间的潜在疗效变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们分析了西中国医院接受ICIS治疗的不可切除，局部先进或转移性BTC的患者（2019年1月至2023年10月）。主要终点是总生存期（OS），而次要终点包括无进展生存率（PFS），客观反应率（ORR），疾病控制率（DCR）和安全性。 Kaplan-Meier生存曲线，倾向评分匹配（PSM）和COX比例危害回归分析了治疗疗效。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共有221名高级BTC患者。其中，有137名患者在第一行接受ICIS治疗，而第二次或更高版本的患者有84例。对于以ICI为一线治疗的患者，中位OS​​为15.7个月（95％CI：13.1-19.8），PFS为8.4个月（95％CI：7.6-10.3）。相比之下，在第二或以后进行治疗的患者中位OS较短为9.8个月（95％CI：8.1-12.3），中位PFS为5.6个月（95％CI：4.2-6.8）。与一线接受者相比，以后治疗中降低的疗效可能反映了先前的治疗性耐药性和通常较差的患者状况。 211（95.5％）患者至少经历了一个不良事件（AE），其中93例（42.1％）经历了3级或更高的AE。与免疫相关的不良事件（IRAE）的发生率为35.8％，其中8.6％的患者患有3-4级IRAE。最常见的ICI治疗方法是使用Durvalumab或sintilimab，我们对比较感兴趣。杜瓦卢马布（Durvalumab）在数值上具有优势OS与Sintilimab（19.3 vs 10.2个月，p &lt;0.001）在无与伦比的分析中显示，尽管显着性在PSM后减弱（16.1 vs 13.1个月，p = 0.299）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：ICIS在现实世界中表现出强大的功效和可管理的毒性，支持它们在先进BTC的第一和后期治疗中的使用。但是，国内ICI替代方案是否仍然可行，需要进一步验证。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230857/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230857</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994646/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994646</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1493234>10.3389/fimmu.2025.1493234</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230857</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Yichen Zheng</dc:creator><dc:creator> Jiamin Guo</dc:creator><dc:creator> Tonghui Ren</dc:creator><dc:creator> JI MA</dc:creator><dc:creator>丹曹</dc:creator><dc:date>2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>免疫检查点抑制剂在晚期胆道癌中的功效和安全性：一项现实研究</dc:title><dc:identifier>PMID：40230857</dc:identifier><dc:identifier> PMC：PMC11994646</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1493234</dc:identifier></item><item><title>成功治疗初级难治性DLBCL/HGBL -MYC/BCL2使用Glofitamab转变为FL：病例报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230856/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>弥漫性大型B细胞淋巴瘤/高级B细胞淋巴瘤具有MYC和BCL2重排（DLBCL/HGBL-MYC/BCL2）代表了成熟的攻击性B细胞淋巴瘤的独特实体，在DLBCL的临床管理中构成了大量的差距。常规的R-CHOP样化学免疫疗法方案表明，DLBCL/HGBL-MYC/BCL2的功效有限，临床结果仍然很差，中位总生存率少于2年，甚至在从...转变为...的情况下甚至更短。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1566035。 doi：10.3389/fimmu.2025.1566035。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">弥漫性大型B细胞淋巴瘤/高级B细胞淋巴瘤具有<i>MYC</i>和<i>BCL2</i>重排（DLBCL/HGBL- <i>MYC</i> / <i>BCL2</i> ）代表了成熟攻击性B细胞淋巴瘤的独特实体，在DLBCL的临床管理中构成了大量的差距。常规的R-CHOP样化学免疫疗法方案表明，DLBCL / HGBL- <i>MYC</i> / <i>BCL2</i>的功效有限，临床结局仍然很差，中位总生存率少于2年，甚至在从昏暗淋巴瘤中转变的病例中甚至更短。我们报道说，一名66岁的女性首先被诊断为卵泡淋巴瘤，但在用BR疗法治疗期间出现了疾病进展到DLBCL / HGBL- <i>MYC</i> / <i>BCL2</i> 。此外，患者也是Pola-R-CHP的主要难治性。用CD20×CD3双特异性抗体Glofitamab治疗后，患者获得了部分反应，并保持了长期缓解。尽管仅提出了一个成功的病例，但Glofitamab可以被视为用于转化的复发/难治性DLBCL/HGBL- <i>myc</i> / <i>bcl2</i>的打捞疗法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230856/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230856</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994609/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994609</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1566035>10.3389/fimmu.2025.1566035</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230856</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator>明昆格楚</dc:creator><dc:creator>Ting-Juan Zhang</dc:creator><dc:creator>元冯</dc:creator><dc:creator>Xun Shao</dc:creator><dc:creator> Yong-hui ji</dc:creator><dc:creator> Jun Qian</dc:creator><dc:creator> Jing-dong周</dc:creator><dc:date>2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>成功治疗初级难治性DLBCL/HGBL -MYC/BCL2使用Glofitamab转变为FL：病例报告</dc:title><dc:identifier>PMID：40230856</dc:identifier><dc:identifier> PMC：PMC11994609</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1566035</dc:identifier></item><item><title>跟踪富裕市社区居民的SARS-COV-2感染后血清抗体水平和影响因素的演变</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230855/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>结论：年轻人，没有运营历史的人，没有吸烟史的人，第一次感染后有典型症状的人和持续持续超过第一次感染后2周以上的症状。通常，IgG抗体的水平通常降低，因此有必要增强免疫接种。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1533102。 doi：10.3389/fimmu.2025.1533102。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：跟踪富州居民中血清抗体的水平，并分析血清抗体的可能影响因素，以便为调整种群免疫和预防和控制策略的科学基础提供科学基础。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：自2022年12月自2022年12月以来，富裕社区的居民对核酸或抗原进行了呈阳性的居民进行问卷调查，并收集了其血清以分析抗体变化的趋势，将抗体水平划分为高抗体组和低抗体组，并根据文献数据分配为低抗体组。通过多元逻辑回归模型分析了血清抗体水平的可能影响因子。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：研究中总共采用了2,521名富裕居民，其中高抗体组的223个和低抗体组的194个。 A univariate analysis showed that, there were significant differences in age (Z=-4.028, P&lt;0.00), occupation (χ <sup>2</sup> = 18.591, P=0.005), typical symptoms after the first infection (χ <sup>2</sup> = 9.784, P=0.002), history of surgery (χ <sup>2</sup> = 29.542, P&lt;0.001), symptoms lasting more than 2 weeks after the first infection (χ <sup>2</sup> = 4.887，p = 0.027），吸烟（ <sup>χ2</sup> = 18.524，p &lt;0.001）和饮用（ <sup>χ2</sup> = 19.578，p &lt;0.001）和低抗体组之间。 Multivariate regression models show that, age (OR= 1.011, 95%CI: 1.002~1.020, P=0.017), history of surgery (OR=4.956,95%CI: 2.606~9.423, P&lt;0.001),smoking (OR=2.089, 95%CI: 1.002~4.355, P=0.049), drinking (OR=2.214, 95％CI：1.066〜4.600，p = 0.033）是影响抗体水平的风险因素。第一次感染后的典型症状（OR = 0.224，95％CI：0.086〜0.579，p = 0.002），症状持续了第一次感染后2周以上（OR = 0.432，95％CI：0.258〜0.723，p = 0.001）是保护因素。通过观察3、6和9个月内抗体变化的趋势，我们发现IgG抗体的水平显示出趋势下降。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：年轻人，没有运营历史的人，没有吸烟史的人，第一次感染后有典型症状的人和持续持续超过第一次感染后2周以上的症状。通常，IgG抗体的水平通常降低，因此有必要增强免疫接种。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230855/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230855</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994895/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994895</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1533102>10.3389/fimmu.2025.1533102</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230855</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator>小子郑</dc:creator><dc:creator>青金陈</dc:creator><dc:creator>Qiangbing Liao</dc:creator><dc:creator>肖张</dc:creator><dc:date>2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>跟踪富裕市社区居民的SARS-COV-2感染后血清抗体水平和影响因素的演变</dc:title><dc:identifier>PMID：40230855</dc:identifier><dc:identifier> PMC：PMC11994895</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1533102</dc:identifier></item><item><title>发现与CD8 &lt;sup>;+&lt;/sup>; T细胞浸润有关的生物标志物，并使用单细胞RNA测序和基因共表达网络中结肠腺癌中肿瘤相关的纤维化</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230854/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>结论：这项研究已经确定了与CD8^（+）T细胞相关的三个关键基因和COAD的预后，为诊断和治疗COAD提供了新的预后生物标志物。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1496640。 doi：10.3389/fimmu.2025.1496640。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：结直肠腺癌（COAD）是与高死亡率相关的普遍恶性肿瘤。在肿瘤微环境中，CD8 <sup>+</sup> T细胞在人体内的抗肿瘤免疫反应中起关键作用。纤维化直接和间接影响肿瘤免疫疗法的治疗反应。然而，与肿瘤相关的纤维化和CD8 <sup>+</sup> T细胞浸润有关的调节基因的重要性仍然不确定。因此，必须确定具有预后价值的生物标志物，并阐明CD8 <sup>+</sup> T细胞和与肿瘤相关的纤维化的精确作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对GEO数据库的COAD样品进行了单细胞转录组分析。为了评估COAD样品中的免疫浸润，我们利用了Cibersort和估计。此外，我们分析了CD8 <sup>+</sup> T细胞与免疫浸润之间的相关性。为了分析COAD表达的定量免疫细胞组成数据，我们进行了加权基因相关网络分析并使用了反卷积算法。这些分析的数据是从GEO数据库中获得的。我们利用单变量的COX回归和套索分析来创建预后模型。通过Kaplan-Meier分析评估了预测模型，并创建了生存预测列图。此外，我们分析了预后模型与化学疗法药物敏感性之间的相关性。为了估计轮毂基因的表达，我们采用了免疫组织化学，实时PCR和Western印迹技术。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：单细胞转录组分析表明，COAD肿瘤样品中CD8 <sup>+</sup> T细胞的患病率更高。通过WGCNA和使用GEO数据库进行反卷积分析，进一步证实了COAD和CD8 <sup>+</sup> T细胞之间的连接。蛋白质 - 蛋白质相互作用网络分析揭示了三个集线器基因： <i>LARS2</i> ， <i>SEZ6L2</i>和<i>SOX7</i> 。随后使用套索和单变量COX回归创建了一个预测模型，其中包括这三个基因。这些集线器基因中的两个（ <i>LARS2</i>和<i>SEZ6L2</i> ）被发现在CoAD细胞系和组织中上调，而<i>Sox7</i>被下调。预后模型与CD8 <sup>+</sup> T细胞有显着关联，表明这些基因可以作为治疗COAD中基因治疗的潜在生物标志物和靶标。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究确定了与CD8 <sup>+</sup> T细胞相关的三个关键基因和COAD的预后，提供了用于诊断和治疗COAD的新预后生物标志物。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40230854/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230854</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994618/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994618</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1496640>10.3389/fimmu.2025.1496640</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40230854</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Jinning Zhang</dc:creator><dc:creator> Ziquan Sun</dc:creator><dc:creator>库登·李</dc:creator><dc:creator>利克西亚叮当</dc:creator><dc:creator>Zitong Wang</dc:creator><dc:creator>明刘</dc:creator><dc:date>2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>发现与CD8 &lt;sup>;+&lt;/sup>; T细胞浸润有关的生物标志物，并使用单细胞RNA测序和基因共表达网络中结肠腺癌中肿瘤相关的纤维化</dc:title><dc:identifier>PMID：40230854</dc:identifier><dc:identifier> PMC：PMC11994618</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1496640</dc:identifier></item><item><title> Keloid和炎症：IL-33在表皮变化中的关键作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/40230853/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250415082127＆v = 2.18.0.post9+e462414<description>简介：乳子状体是良性纤维增生性疾病，其特征是过度胶原蛋白沉积和炎症，超出了原始伤口边界。 IL-33是在细胞损伤或应力下释放的警报细胞因子。表皮角质形成细胞中IL-33的失调会损害皮肤屏障，并触发慢性炎症。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年3月31日； 16：1514618。 doi：10.3389/fimmu.2025.1514618。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：乳子状体是良性纤维增生性疾病，其特征是过度胶原蛋白沉积和炎症，超出了原始伤口边界。 IL-33是在细胞损伤或应力下释放的警报细胞因子。表皮角质形成细胞中IL-33的失调会损害皮肤屏障，并触发慢性炎症。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项研究中，我们首先注意到通过组织学染色，IL-33在角膜表皮角质形成细胞中的表达增加。然后，通过组织学染色和流式细胞仪分析鉴定出渗透淋巴样真皮的淋巴细胞中IL-33受体（ST2）的表达增加。流式细胞术和蛋白质印迹分析进一步揭示了淋巴细胞和角质形成细胞之间的IFN-γ-IL-33环路。 The abnormal keratinocyte differentiation in epiderm is mediated by IFN-γ-IL-33 loop were confirmed by <i>in vitro</i> studies in HaCaT cells via Western blotting analysis and immunofluorescence staining. Finally, the IFN-γ-IL-33 loop were also verified in cocultured peripheral blood mononuclear cells and HaCaT through ELISA analysis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Our results demonstrate that IL-33 levels are significantly elevated in the epidermis of keloid tissues, where it functions as an alarmin, promoting a chronic inflammatory response. We further reveal a feedback loop between IL-33 and interferon-gamma (IFN-γ), whereby IL-33 induces IFN-g production in lymphocytes, which in turn stimulates keratinocytes to produce more IL-33. This loop contributes to impaired keratinocyte differentiation and skin barrier dysfunction, exacerbating the inflammatory environment. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DISCUSSION: By elucidating the role of the IL-33/ST2 axis in keloid formation, this research provides valuable insights into potential therapeutic targets for managing this challenging condition.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40230853/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230853</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994421/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994421</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1514618>10.3389/fimmu.2025.1514618</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40230853</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> ZongAn Chen</dc:creator><dc:creator> YaTing Yang</dc:creator><dc:creator> XiuXia Wang</dc:creator><dc:creator> LingLing Xia</dc:creator><dc:creator> WenBo Wang</dc:creator><dc:creator> XiaoLi Wu</dc:creator><dc:creator> Zhen Gao</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>Keloids and inflammation: the crucial role of IL-33 in epidermal changes</dc:title><dc:identifier> pmid:40230853</dc:identifier><dc:identifier> pmc:PMC11994421</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1514618</dc:identifier></item><item><title> The protective effect of &lt;em>;Chlorella vulgaris&lt;/em>; against diclofenac toxicity in &lt;em>;Clarias gariepinus&lt;/em>;: haemato-immunological parameters and spleen histological features as outcome markers</title><link/> https://pubmed.ncbi.nlm.nih.gov/40230852/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250415082127&amp;v=2.18.0.post9+e462414<description> CONCLUSION: These findings suggest that dietary inclusion of C. vulgaris may antagonize the haemato-cytological abnormalities induced by DCF intoxication. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 31;16:1566496. doi: 10.3389/fimmu.2025.1566496.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: Diclofenac (DCF) is a commonly utilized medication in the non-steroidal anti-inflammatory drug category that is released into aquatic systems in significant amounts. Chlorella vulgaris (C. vulgaris) is rich in active phytochemicals known for their haemato-immunological boosting properties. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Our objective was to investigate the haemato-immunological protective properties of Chlorella in mitigating the toxic effects of DCF. Five groups of Clarias gariepinus, each comprising 36 fish, were assigned over a two-week period. The groups were assigned as follows: control group, which received a basal diet only; DCF1 group, which received a basal diet and was exposed to 20 μg/L of DCF; DCF2 group, which received a basal diet and was exposed to 10 mg/L of DCF; and Chlorella +DCF1 and Chlorella+DCF2 groups, which were exposed to the same DCF doses as Groups 2 and 3, respectively, while also being fed a diet containing 25% Chlorella. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Exposure to both doses of DCF significantly decreased erythrocyte count, hemoglobin content, white blood cell count, phagocytic index, and lysozyme activity, while increased eosinophil and neutrophil % in an equipotent manner. The low dose caused a more pronounced reduction in packed cell volume (PCV)% and large lymphocyte% compared to the high dose. A significant decline in platelet count was observed only with the low DCF dose, while the high dose led to a decrease in monocyte%. DCF intoxication led to a dose-related decrease in small lymphocyte% and an increase in erythrocyte morphological alterations and interleukin (IL)-6 levels. The DCF2 group exhibited a higher increase in apoptotic RBCs than the DCF1 group. Intervention with Chlorella alongside the two DCF doses significantly normalized RBC count and eosinophil %, increased PCV% and small lymphocyte%, and decreased erythrocyte abnormalities to an equal extent. Large lymphocyte% in the Chlorella+DCF1 group was successfully restored to normal levels. Phagocytic index and lysozyme activity in the supplemented groups were lower, while IL-6 levels were higher than in the DCF groups. The percentage of apoptotic cells decreased with Chlorella administration, with the Chlorella+DCF1 group showing fewer apoptotic cells than the Chlorella+DCF2 group. Histopathological deterioration and excessive collagen deposition were observed in the spleen of DCF groups, while notable improvements were seen following C. vulgaris supplementation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: These findings suggest that dietary inclusion of C. vulgaris may antagonize the haemato-cytological abnormalities induced by DCF intoxication.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40230852/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230852</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994428/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994428</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1566496>10.3389/fimmu.2025.1566496</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40230852</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Ahmed Gabr</dc:creator><dc:creator> Amr M Mohamed</dc:creator><dc:creator> Nasser S Abou Khalil</dc:creator><dc:creator> Alaa El-Din H Sayed</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>The protective effect of &lt;em>;Chlorella vulgaris&lt;/em>; against diclofenac toxicity in &lt;em>;Clarias gariepinus&lt;/em>;: haemato-immunological parameters and spleen histological features as outcome markers</dc:title><dc:identifier> pmid:40230852</dc:identifier><dc:identifier> pmc:PMC11994428</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1566496</dc:identifier></item><item><title> CD121b-positive neutrophils predict immunosuppression in septic shock</title><link/> https://pubmed.ncbi.nlm.nih.gov/40230851/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250415082127&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: CD121b is closely associated with the progression of septic shock and may serve as a potential predictor indicator of immunosuppression for the condition. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 31;16:1565797. doi: 10.3389/fimmu.2025.1565797.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Septic shock is linked with high mortality and significant long-term morbidity in survivors. However, the specific role of neutrophils in septic shock pathophysiology remains scarce in recent research. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Peripheral blood immune cells from healthy donors and patients with septic shock were analyzed using single-cell RNA sequencing and batch RNA sequencing. We measured serum CD121b in both patients and healthy donors. Peripheral immune cells were isolated and exposed to either a CD121b recombinant protein or a CD121b blocking antibody to evaluate the expression of inflammatory factors. Additionally, in a humanized mouse sepsis model, the expression of CD121b in neutrophils across different tissues was assessed following treatment with all-trans retinoic acid (ATRA). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: This study identified a subset of CD10 <sup>-</sup> CD121b <sup>+</sup> neutrophils in the peripheral blood of patients with septic shock. These patients exhibited elevated concentrations of soluble CD121b in serum and urine. Furthermore, outcomes revealed that the presence of CD121b <sup>+</sup> neutrophils positively correlated with the severity of septic shock. These cells displayed immunosuppressive characteristics; after blocking CD121b, proinflammatory cytokines increased in peripheral immune cells. Additionally, we found that treatment with ATRA down-regulated the expression of CD121b. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: CD121b is closely associated with the progression of septic shock and may serve as a potential predictor indicator of immunosuppression for the condition.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40230851/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230851</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994419/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994419</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1565797>10.3389/fimmu.2025.1565797</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40230851</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Jian Chen</dc:creator><dc:creator> Jinghe Zhang</dc:creator><dc:creator> Siao Chen</dc:creator><dc:creator> Jingkun Qin</dc:creator><dc:creator> Xinyu Hu</dc:creator><dc:creator> Shengdi Xi</dc:creator><dc:creator> Lin Zhang</dc:creator><dc:creator> Min Zhou</dc:creator><dc:creator> Yonggang Zhou</dc:creator><dc:creator> Binqing Fu</dc:creator><dc:creator> Haiming Wei</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>CD121b-positive neutrophils predict immunosuppression in septic shock</dc:title><dc:identifier> pmid:40230851</dc:identifier><dc:identifier> pmc:PMC11994419</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1565797</dc:identifier></item><item><title> Tissue-resident macrophages and renal diseases: landscapes and treatment directions</title><link/> https://pubmed.ncbi.nlm.nih.gov/40230850/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250415082127&amp;v=2.18.0.post9+e462414<description> Tissue-resident macrophage (TRM) is a specialized subset of macrophage that resides within specific tissues and organs. TRMs play crucial roles in resisting pathogen invasion, maintaining the homeostasis of the immune microenvironment, and promoting tissue repair and regeneration. The development and function of TRMs exhibit significant heterogeneity across different tissues. Kidney TRMs (KTRMs) originate from both embryonic yolk sac erythro-myeloid progenitors and the fetal liver, demonstrating... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 31;16:1548053. doi: 10.3389/fimmu.2025.1548053.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Tissue-resident macrophage (TRM) is a specialized subset of macrophage that resides within specific tissues and organs. TRMs play crucial roles in resisting pathogen invasion, maintaining the homeostasis of the immune microenvironment, and promoting tissue repair and regeneration. The development and function of TRMs exhibit significant heterogeneity across different tissues. Kidney TRMs (KTRMs) originate from both embryonic yolk sac erythro-myeloid progenitors and the fetal liver, demonstrating the capacity for self-renewal independent of bone marrow hematopoiesis. KTRMs are not only essential for the maintenance of renal homeostasis and the monitoring of microvascular environment, but contribute to renal injury due to inflammation, fibrosis and immune dysfunction in kidneys. In this review, we summarize currently available studies on the regulatory role of KTRMs in processes of renal injury and repair. The altering effects and underlying mechanisms of KTRMs in regulating local tissue cells and immune cells in different renal diseases are reviewed, primarily including lupus nephritis, diabetic nephropathy, renal fibrosis, and renal carcinoma. Understanding the plasticity and immune regulatory functions of KTRMs may offer new insights into the pathogenesis and the exploration of therapeutic strategies of kidney diseases.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40230850/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230850</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994677/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994677</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1548053>10.3389/fimmu.2025.1548053</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40230850</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Zhuojian Qu</dc:creator><dc:creator> Jinjin Chu</dc:creator><dc:creator> Shuyu Jin</dc:creator><dc:creator> Chunjuan Yang</dc:creator><dc:creator> Jie Zang</dc:creator><dc:creator>金张</dc:creator><dc:creator>Donghua Xu</dc:creator><dc:creator> Min Cheng</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>Tissue-resident macrophages and renal diseases: landscapes and treatment directions</dc:title><dc:identifier> pmid:40230850</dc:identifier><dc:identifier> pmc:PMC11994677</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1548053</dc:identifier></item><item><title> ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer</title><link/> https://pubmed.ncbi.nlm.nih.gov/40230849/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250415082127&amp;v=2.18.0.post9+e462414<description> CONCLUSION: This study highlights ESCRT&#39;s potential in tumor detection via pan-cancer analysis, showing expression variations between tumor and normal tissues, its role in cancer progression through the immune microenvironment, and its specificity and sensitivity in detection. The VPS37D gene, with significant variation in breast cancer, predicts patient prognosis and is related to the tumor microenvironment, suggesting that ESCRT is a novel biomarker for early diagnosis and prognosis... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Mar 31;16:1531940. doi: 10.3389/fimmu.2025.1531940.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Studies have shown that ESCRT genes affect cell aging, immune environment, and tumors. BRCA was used to explore its effects on tumor prognosis and therapy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The data sets of Cancer Genome Atlas (TCGA), Genome-Tissue Expression Plan (GTEX), Human Protein Mapping (HPA), Gene Expression Omnibus (GEO), Clinical Proteomic Tumor Analysis Consortium (CPTAC), R software package, and bioinformatics methods were used to mine the potential carcinogenic effects of ESCRT, including the expression level, prognostic value, and immune value of ESCRT in various types of tumor tissues, and the potential function of ESCRT family genes was further verified in breast cancer. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: ESCRT showed significant differential expression in various cancers, such as bladder urothelial carcinoma and liver, cervical, renal, esophageal, head, and neck cancers ( <i>P &lt;</i> 0.05). Abnormal ESCRT expression is associated with poor prognosis in various cancers, such as adrenocortical carcinoma, bladder urothelial carcinoma, breast cancer, and cervical cancer ( <i>P &lt;</i> 0.05). The expression level of ESCRT was significantly associated with immune cell infiltration and the modulation of the stromal/immune score (all <i>P &lt;</i> 0.05). Enrichment analysis showed that ESCRT is associated with immune-related functions and transport signaling pathways in various tumor cells. Moreover, ESCRT serves as an early diagnostic marker for several tumors and is significantly associated with prognosis. This confirms that ESCRT is associated with most immune-infiltrating cells in pan-carcinomas. Taken together, these studies highlight the importance of the ESCRT family gene VPS37D in breast cancer initiation, progression, and immune response. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: This study highlights ESCRT&#39;s potential in tumor detection via pan-cancer analysis, showing expression variations between tumor and normal tissues, its role in cancer progression through the immune microenvironment, and its specificity and sensitivity in detection. The VPS37D gene, with significant variation in breast cancer, predicts patient prognosis and is related to the tumor microenvironment, suggesting that ESCRT is a novel biomarker for early diagnosis and prognosis assessment.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40230849/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">40230849</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11994712/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250415082127&v=2.18.0.post9+e462414">PMC11994712</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1531940>10.3389/fimmu.2025.1531940</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40230849</guid><pubDate> Tue, 15 Apr 2025 06:00:00 -0400</pubDate><dc:creator> Xiao-Rui Chen</dc:creator><dc:creator> Xue-Ying Tan</dc:creator><dc:creator> Zong-Liang Zhang</dc:creator><dc:creator> Jiang-Shui Yuan</dc:creator><dc:creator> Wei-Qing Song</dc:creator><dc:date> 2025-04-15</dc:date><dc:source>免疫学领域</dc:source><dc:title>ESCRT may function as a tumor biomarker, transitioning from pan-cancer analysis to validation within breast cancer</dc:title><dc:identifier> pmid:40230849</dc:identifier><dc:identifier> pmc:PMC11994712</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1531940</dc:identifier></item></channel></rss>